Lyell Immunopharma (LYEL) AI Stock Analysis

• Market Cap: $144.38M
• Dividend Yield: N/A
• Average Volume (3M): 237.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.92
• Revenue Growth: -4.41%
• EPS Growth: -38.08%
• Country: US
• Employees: 300
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -3.54
• Shares Outstanding: 14,808,078
• 10 Day Avg. Volume: 47,827
• 30 Day Avg. Volume: 237,569
• PEG Ratio: -0.09
• Price to Book (P/B): 0.42
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.81
• Enterprise Value/Market Cap: 0.49
• Enterprise Value/Revenue: 289.95
• Enterprise Value/Gross Profit: 1.08K
• Enterprise Value/Ebitda: -0.09
• 1Y Price Target: $10.17
• Price Target Upside: 4.31% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 47 Neutral
• Price Target: $10.00 ▲(2.56%Upside)

Lyell Immunopharma's overall stock score is primarily impacted by its significant financial challenges and poor valuation metrics. While technical indicators show some positive momentum, the lack of revenue and persistent losses weigh heavily on the stock's outlook. Promising trial results provide a potential future catalyst, but immediate financial risks remain high.

Positive Factors

Financial Resources

Lyell ended 4Q24 with $383.5 million in cash, which management expects to provide an operational runway into 2027.

Regulatory Support

RMAT designation for LYL314 is a positive sign in turbulent times at the FDA.

Negative Factors

Financial Performance

Lyell reported a net loss of $0.69 per share, which was worse than the analyst's estimate of a net loss of $0.18 per share.

Market Competition

The CD19-targeted CAR-T space is considered crowded and may not support another entrant with the current under $3 billion aggregated annual sales across competitors.

Strategic Uncertainty

The decision to discontinue next-gen, early-stage, solid tumor CAR-T LYL119 adds to the uncertainty surrounding Lyell's strategy.

Lyell Immunopharma Business Overview & Revenue Model

Company Description

Lyell Immunopharma (LYEL) is a biotechnology company focused on developing innovative T-cell therapies for the treatment of cancer. The company's mission is to overcome the limitations of current cell therapies by enhancing the functionality and persistence of T-cells. Lyell is committed to transforming the lives of cancer patients by providing more effective and durable treatment options through its advanced research and development efforts in the field of immunotherapy.

How the Company Makes Money

Lyell Immunopharma generates revenue primarily through strategic collaborations and partnerships with pharmaceutical and biotechnology companies. These partnerships often involve licensing agreements, milestone payments, and royalties associated with the development and commercialization of T-cell therapies. Additionally, Lyell may receive funding from grants and research collaborations aimed at advancing their scientific innovations. The company also invests in developing proprietary technologies and seeks to monetize these innovations through clinical success, leading to potential product sales and additional partnerships.

Lyell Immunopharma Financial Statement Overview

Summary

Lyell Immunopharma faces financial challenges with zero revenue and persistent losses. The balance sheet is stronger, showing low debt and a solid equity base, but cash flow is strained with reliance on financing.

Income Statement

Lyell Immunopharma has faced significant challenges in revenue generation, with revenue dropping to zero in the latest year. The company has consistently reported negative net income, resulting in negative net profit margins. The absence of revenue and persistent losses indicate financial difficulties in scaling operations or commercializing products.

Balance Sheet

The balance sheet shows a strong equity position with a low debt-to-equity ratio, reflecting financial prudence. However, the decline in stockholders' equity over the years may indicate operational challenges. The equity ratio remains healthy, suggesting solid capital management despite operational losses.

Cash Flow

Lyell Immunopharma's cash flow statement highlights significant operating cash outflows due to ongoing losses. While free cash flow remains negative, the company has maintained a consistent level of cash reserves. The ability to generate positive cash flow from financing activities has been crucial in sustaining operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	65.00K	61.00K	130.00K	84.68M	10.65M	7.76M
Gross Profit	65.00K	61.00K	130.00K	68.22M	-3.88M	281.00K
EBITDA	-204.02M	-200.64M	-226.76M	-166.65M	-199.94M	-207.64M
Net Income	-334.52M	-342.99M	-234.63M	-4.75M	-285.50M	-198.53M
Balance Sheet
Total Assets	429.80M	490.86M	750.03M	937.56M	1.13B	908.28M
Cash, Cash Equivalents and Short-Term Investments	301.18M	370.53M	546.22M	640.15M	614.79M	612.62M
Total Debt	48.85M	58.97M	63.17M	67.70M	67.82M	54.57M
Total Liabilities	93.28M	108.03M	95.08M	104.31M	197.62M	189.84M
Stockholders Equity	336.52M	382.82M	654.95M	833.25M	929.79M	718.44M
Cash Flow
Free Cash Flow	-175.80M	-162.86M	-166.38M	-193.83M	-191.75M	-212.35M
Operating Cash Flow	-175.12M	-162.39M	-163.69M	-169.56M	-126.25M	-160.87M
Investing Cash Flow	169.90M	122.42M	184.05M	-11.54M	-121.57M	-273.52M
Financing Cash Flow	1.30M	1.33M	1.74M	10.63M	401.24M	476.79M

Lyell Immunopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.75
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYEL, the sentiment is Positive. The current price of 9.75 is above the 20-day moving average (MA) of 9.46, above the 50-day MA of 9.23, and below the 200-day MA of 14.09, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 51.96 is Neutral, neither overbought nor oversold. The STOCH value of 73.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LYEL.

Lyell Immunopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SEER	55 Neutral	$128.87M	―	-24.73%	―	-1.02%	-8.59%
Sector *	52 Neutral	$7.51B	0.24	-62.67%	2.30%	16.09%	0.95%
ADCT	51 Neutral	$327.29M	―	123.38%	―	10.49%	47.31%
FATE	50 Neutral	$132.97M	―	-49.23%	―	105.85%	22.13%
LYEL	47 Neutral	$144.38M	―	-71.20%	―	-4.41%	-38.08%
FDMT	46 Neutral	$198.27M	―	-32.97%	―	―	―
NKTX	39 Underperform	$127.72M	―	-26.10%	―	―	30.76%

Lyell Immunopharma Corporate Events

Lyell Immunopharma Announces Promising CAR T-Cell Trial Data

On June 17, 2025, Lyell Immunopharma announced new clinical data from its ongoing Phase 1/2 trial of LYL314, a CAR T-cell therapy for large B-cell lymphoma (LBCL). The trial showed promising results with high overall response rates and manageable safety profiles in both third- or later-line (3L+) and second-line (2L) settings. The company plans to initiate a randomized pivotal trial by early 2026 and has the manufacturing capacity to support clinical development and early commercial launch if approved.

The most recent analyst rating on (LYEL) stock is a Hold with a $80.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.

Lyell Immunopharma Expands Board, Appoints New Director

On June 9, 2025, Lyell Immunopharma‘s Board of Directors expanded from seven to eight members, appointing Mark Bachleda, Pharm.D., M.B.A., as a Class I director. Dr. Bachleda will serve until the 2028 annual stockholders meeting, receiving compensation and equity grants as per the company’s policy, adjusted for a recent reverse stock split.

The most recent analyst rating on (LYEL) stock is a Hold with a $80.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.

Lyell Immunopharma Announces 1-for-20 Reverse Stock Split

On May 27, 2025, Lyell Immunopharma announced a reverse stock split at a 1-for-20 ratio, authorized by its stockholders during the annual meeting on May 15, 2025. Effective May 30, 2025, this move will consolidate every 20 shares into one, adjusting stock options and equity plans proportionately, with trading on a split-adjusted basis starting June 2, 2025, on Nasdaq. This action aims to streamline the company’s stock structure without altering shareholders’ proportional ownership.

The most recent analyst rating on (LYEL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.

Lyell Immunopharma Stockholders Approve Key Proposals

On May 15, 2025, Lyell Immunopharma held its annual meeting of stockholders virtually, with 71.9% of shares represented, constituting a quorum. Stockholders voted on four proposals, including the election of Catherine Friedman as a director, ratification of Ernst & Young LLP as auditors, approval of executive compensation, and potential reverse stock split amendments, all of which were passed.

The most recent analyst rating on (LYEL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.